Invivo Rat anti-Mouse CD276 Recombinant mAb
Invivo Rat anti-Mouse CD276 Recombinant mAb
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | Mouse CD276 |
| Synonyms | CD276 antigen; B7 homolog 3 (B7-H3); Costimulatory molecule; B7h3 |
| Location | Membrane |
| Accession | Q8VE98 |
| Clone Number | S-R633 |
| Antibody Type | Rat mAb |
| Isotype | Rat IgG1,k |
| Application | in vivo B7-H3 blockade |
| Reactivity | Ms |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Endotoxin | <2EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage |
2 to 8 °C for 2 weeks under sterile conditions; -20 °C for 3 months under sterile conditions; -80 °C for 24 months under sterile conditions.
Please avoid repeated freeze-thaw cycles.
|
Background
CD276 (B7-H3) is an immune checkpoint molecule belonging to the B7 family and encodes a type I transmembrane protein. It plays a role in regulating T cell-mediated immune responses. CD276 is highly expressed in various tumor cells and tumor-infiltrating immune cells, aiding tumor cells in evading immune surveillance and promoting tumor proliferation, metastasis, and treatment resistance. Additionally, CD276 is associated with cancer stem cell properties, and its high expression is linked to poor prognosis. Currently, several targeted therapies against CD276, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies, are under development and in clinical trials, showing promising anti-tumor potential.
